Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ROIV 
Roivant Sciences Ltd (ROIV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ROIV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $20.05
1 Year Target Price $20.05
| 6 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.44% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.68B USD | Price to earnings Ratio - | 1Y Target Price 20.05 |
Price to earnings Ratio - | 1Y Target Price 20.05 | ||
Volume (30-day avg) 10 | Beta 1.2 | 52 Weeks Range 8.73 - 17.32 | Updated Date 10/17/2025 |
52 Weeks Range 8.73 - 17.32 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -12839.72% |
Management Effectiveness
Return on Assets (TTM) -12.59% | Return on Equity (TTM) -18.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6508993253 | Price to Sales(TTM) 502.91 |
Enterprise Value 6508993253 | Price to Sales(TTM) 502.91 | ||
Enterprise Value to Revenue 280.16 | Enterprise Value to EBITDA 0.74 | Shares Outstanding 682881743 | Shares Floating 417691447 |
Shares Outstanding 682881743 | Shares Floating 417691447 | ||
Percent Insiders 26.12 | Percent Institutions 76.82 |
Upturn AI SWOT
Roivant Sciences Ltd
Company Overview
History and Background
Roivant Sciences Ltd. was founded in 2014 by Vivek Ramaswamy. It focuses on acquiring and developing promising drug candidates from larger pharmaceutical companies that may have been deprioritized. Roivant utilizes a 'Vant' structure, creating subsidiary companies focused on specific therapeutic areas or assets.
Core Business Areas
- Drug Development: Acquiring and developing pharmaceutical products across various therapeutic areas.
- Vant Creation: Creating and managing Vants (subsidiary companies) focused on specific therapeutic areas.
- Technology Platform: Utilizing a technology platform to improve drug development and commercialization efficiency.
Leadership and Structure
Matt Gline is the CEO. The company operates with a decentralized structure, with each Vant having its own management team.
Top Products and Market Share
Key Offerings
- VTAMA (tapinarof): A topical cream for the treatment of plaque psoriasis and atopic dermatitis. Market share is growing, but specific figures are proprietary. Competitors include topical corticosteroids, vitamin D analogs, and other novel therapies. Revenue for 2023 for VTAMA was $234 Million. Competitors include Amgen (AMGN), Bristol Myers Squibb (BMY)
- RVT-3101 (Batoclimab): An anti-FcRn antibody being developed for multiple autoimmune diseases. Market share is not yet established, as the drug is still in clinical trials. Competitors include argenx (ARGX), UCB (UCB)
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and patent protection. It's a large and growing market driven by aging populations and increasing prevalence of chronic diseases.
Positioning
Roivant is positioned as an innovator in drug development, focusing on de-risked assets and leveraging a technology-driven approach to improve efficiency. Competitive advantages include its Vant structure and data analytics capabilities.
Total Addressable Market (TAM)
The total pharmaceutical market is estimated to be over $1 trillion. Roivant's positioning within this TAM targets niche areas with significant unmet needs. It focuses on autoimmune market which is expect to grow to be more than $150 Billion in the coming years.
Upturn SWOT Analysis
Strengths
- Innovative business model (Vant structure)
- Strong data analytics capabilities
- Experienced management team
- Diversified portfolio of drug candidates
- Strategic partnerships
Weaknesses
- Reliance on external funding
- High R&D spending
- Dependence on clinical trial success
- Complexity of managing multiple Vants
- History of some clinical trial failures
Opportunities
- Expansion into new therapeutic areas
- Acquisition of additional drug candidates
- Strategic partnerships with pharmaceutical companies
- Utilization of AI and machine learning to accelerate drug development
- Potential for breakthrough therapies
Threats
- Regulatory changes
- Competition from established pharmaceutical companies
- Clinical trial failures
- Patent expirations
- Economic downturn
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- ABBV
- MRK
- BMY
Competitive Landscape
Roivant differentiates itself through its Vant structure and focus on de-risked assets. However, it faces competition from larger, more established pharmaceutical companies with greater resources.
Major Acquisitions
Silicon Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 450
- Strategic Rationale: To enhance its computational drug discovery capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by acquisitions, clinical trial progress, and the expansion of the Vant portfolio.
Future Projections: Future growth depends on clinical trial successes, regulatory approvals, and successful commercialization of its drug candidates. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing clinical trials for key drug candidates and forming strategic partnerships.
Summary
Roivant Sciences is a unique company that identifies and develops promising drug candidates, it also leverages a technology-driven approach. Its decentralized Vant structure promotes nimbleness, but requires oversight and resources. The company's success hinges on clinical trial outcomes and regulatory approvals. Roivant faces competition from well-established pharmaceutical giants but also has the potential to grow rapidly through strategic acquisitions and innovative drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Roivant Sciences Ltd. Investor Relations
- Company Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Roivant Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-10-01 | CEO & Director Mr. Matthew Gline | ||
Sector Healthcare | Industry Biotechnology | Full time employees 750 | Website https://roivant.com |
Full time employees 750 | Website https://roivant.com | ||
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.